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The developmental and epileptic encephalopathies (DEE) are a group of rare, severe neurodevelopmental disorders, where even
the most thorough sequencing studies leave 60–65% of patients without a molecular diagnosis. Here, we explore the
incompleteness of transcript models used for exome and genome analysis as one potential explanation for a lack of current
diagnoses. Therefore, we have updated the GENCODE gene annotation for 191 epilepsy-associated genes, using human brain-
derived transcriptomic libraries and other data to build 3,550 putative transcript models. Our annotations increase the
transcriptional ‘footprint’ of these genes by over 674 kb. Using SCN1A as a case study, due to its close phenotype/genotype
correlation with Dravet syndrome, we screened 122 people with Dravet syndrome or a similar phenotype with a panel of exon
sequences representing eight established genes and identiﬁed two de novo SCN1A variants that now - through improved gene
annotation - are ascribed to residing among our exons. These two (from 122 screened people, 1.6%) molecular diagnoses carry
signiﬁcant clinical implications. Furthermore, we identiﬁed a previously classiﬁed SCN1A intronic Dravet syndrome-associated
variant that now lies within a deeply conserved exon. Our ﬁndings illustrate the potential gains of thorough gene annotation in
improving diagnostic yields for genetic disorders.
npj Genomic Medicine            (2019) 4:31 ; https://doi.org/10.1038/s41525-019-0106-7
INTRODUCTION
The developmental and epileptic encephalopathies (DEE) are a
heterogeneous group of rare neurodevelopmental disorders,
characterised by (a) early-onset seizures that are often intractable,
(b) electroencephalographic abnormalities, (c) developmental
delay or regression and (d) in some cases, early death.1,2 One of
the most well-characterised DEEs is Dravet syndrome (DS),
previously known as Severe Myoclonic Encephalopathy of Infancy
(SMEI). DS presents as prolonged febrile seizures within the ﬁrst
year of life in an otherwise healthy child, evolving into intractable
febrile and afebrile seizures with developmental plateauing or
regression in the next few years. DS is genetically one of the most
homogeneous DEEs, with more than 80% of people shown to
carry a de novo SCN1A variant.3 Large-scale international research
efforts such as Epi25 <http://epi-25.org/>, the Deciphering
Developmental Disorders (DDD) study4 and the UK 100,000
Genomes Project5 are now concentrating on diagnosing people
and identifying genes involved in rare disorders including DEE,
using chromosomal microarrays, whole exome sequencing (WES)
and whole genome sequencing (WGS). However, while numerous
genes associated with other forms of DEE are being uncovered,
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between 60–65% of people remain without a molecular
diagnosis.6,7
The ability to infer clinical information about a patient’s
genome, relies upon reference data sets that help to make
informed decisions about putative causative variants. Therefore,
the conﬁdence of such decisions is dependent upon the reliability
of the underlying data against which a patient’s genome is
analysed. For example, the human genome reference sequence is
still incomplete, which is demonstrated by the work that the
Genome Reference Consortium (GRC) is undertaking to ﬁll
remaining sequence gaps, as well as representing different
population haplotypes.8 However, the incompleteness of the
human transcriptome should also be a consideration for genome
interpretation, since a complete set of transcripts from all the
different tissue types and developmental stages that are naturally
present is not yet available. Until it is possible to conﬁdently
generate a de novo genome assembly for a patient, in conjunction
with a complete transcriptome (and for example, proteome),
researchers and clinicians must rely upon data that is available in
public databases.
Therefore, improvements in diagnostics can, in part, be
achieved through improvements in gene annotation. At the
current time, most GENCODE (i.e. Ensembl)9 and RefSeq10 gene
annotations are based on cDNA and EST libraries produced
alongside the initial experimental phase of the Human Genome
Project, while the large datasets produced by more recent RNA-
Seq and long-read sequencing-based projects remain largely
unincorporated. Such datasets have the potential to add exons via
transcript models to existing gene annotations and these features
can provide new insights into genetic disease. For example,
‘expanded’ exomes offer the potential to capture additional
disease-linked variants beyond the reach of previous studies.
Additional sequences can be added to existing exome ‘panels’
used for diagnostics in the clinic and used to select regions for
resequencing in people without a molecular genetic diagnosis.
Indeed, this has already been demonstrated for DLG2, where
newly identiﬁed exons were observed to be deleted in people
with neurodevelopmental disorders.11 Furthermore, the resequen-
cing of annotated regions identiﬁed previously missed pathogenic
variants linked to epilepsy in SCN8A.12 Meanwhile, additional
transcript features can also be used to reappraise existing
variation datasets; providing, for example, new mechanistic
explanations for known disease-associated variants and also
allowing for the reconsideration of variants from whole-genome
studies that had previously been de-prioritised due to an apparent
lack of transcription.
In fact, modern transcriptomics datasets have the potential to
add an enormous number of transcribed features to gene
annotation catalogues and the exact proportion of this ‘transcrip-
tional complexity’ that is linked to gene function and therefore to
phenotype, remains hard to fathom. If a portion of observed
transcription events for a given gene lack functional relevance,
then expanded gene annotations could unknowingly be a source
of misleading variant interpretations. In practice, transcript
functionality is conﬁrmed in the laboratory, although important
insights can be gained from bioinformatics. Evolutionary con-
servation has long been regarded as a strong proxy for
functionality, for example in the observation that coding
sequences (CDS) have been subjected to purifying selection or
that splice sites are constrained and consistently transcribed in
multiple species.13 As such, conservation metrics are commonly
used in transcript interpretation and thus, variant prioritisation.
However, variants linked to poorly conserved transcript features
can also be drivers of genetic disease. In particular, it is now well
established that many genes utilise alternative splicing to reduce
their translational output, redirecting transcription into non-
coding pathways via the incorporation of ‘poison exons’.14 Here,
we classify poison exons as those whose inclusivity in the
transcript cause a CDS change (i.e a frameshift and/or premature
termination codon (PTC)) that is predicted to trigger the
Nonsense-Mediated Decay (NMD) degradation pathway. While
some poison exons are ancient, the mode and tempo of
regulatory splicing evolution in general remains poorly under-
stood.15–17 Alternatively, several recent reports have demon-
strated that gene output can be compromised by variants that
improve the splicing efﬁcacy of poorly conserved transcription
events at the expense of the ‘canonical’ mRNA, i.e. according to a
‘gain of function’ model.18
Here, we explore the potential of expanded gene annotation to
improve the diagnostics of epilepsy, utilising a manual annotation
workﬂow that is initially agnostic with regards to the potential
functionality of these transcript sequences. Overall, this work has
added 3550 GENCODE transcript models to 191 genes associated
with DEE via the utilisation of publicly available short- and long-
read transcriptomics datasets. Subsequently, we create an
expanded exome panel for eight genes associated with DS,
incorporating 125 transcript regions and after resequencing 122
people with a clinical diagnosis of DS or a similar phenotype,
discover two de novo variants within SCN1A exonic sequences.
Both variants are found within presumptive poison exons that
exhibit poor evolutionary conservation. In contrast, we also
demonstrate that a third DS-associated variant, previously
considered to be intronic and of unknown signiﬁcance, is present
in an alternative SCN1A poison exon that has deep conservation.
Although further work is required to understand the biological
implications of the transcriptional complexity associated within
SCN1A and the larger set of 191 genes, our ﬁndings relating to DS
show that from the current bioinformatics perspective, uncertain-
ties regarding transcript functionality are not necessarily a barrier
to the utility of these transcripts in disease genetics.
RESULTS
Manual re-annotation substantially increases the number of
transcripts
We manually re-annotated 191 genes associated with epilepsy as
part of the GENCODE project, primarily using publicly available
long-read transcriptional datasets including brain-derived SLR-Seq
and PacBio Iso-Seq reads (see Methods). In total, 3550 alternatively
spliced transcripts were annotated across the 191 genes,
increasing the number of transcripts for these genes from 1807
to 5357. All transcripts are included in GENCODE v28; contem-
porary RefSeq annotation contains 1397 NM and XM transcripts.
The majority of added transcripts contain either complete exons
(37%) or alternative splice sites within existing exons (21%). In
total, more than 674 kilobases (kb) of additional exonic sequence
was added across the 191 genes.
Next, given the epilepsy context of this study, we further
characterised the transcript regions using existing RNA-Seq data
from pre-frontal cortex in 36 individuals across 6 life stages.19
Introns are generally less well supported than pre-existing introns
(Fig. 1) and just 19% of introns between exons annotated as
coding are covered by at least 10 RNA-Seq reads. However, while
most detectable introns displayed a broadly ubiquitous temporal
expression pattern, a subset of 208 (8%) showed a ﬁvefold
enrichment in expression in foetal versus infant pre-frontal cortex
samples, with 101 showing more than ﬁvefold higher expression
than all other samples combined. This enrichment may highlight a
subset of transcripts of particular functional importance. However,
we recognise that the utility of tissue-speciﬁc expression patterns
to infer functionality remains debatable.20,21
Evolutionary conservation is a commonly used metric of
functional potential.22 Firstly, we mapped all human annotation
for these 191 genes to the mouse reference genome using
TransMap.23 In all, 40% of introns mapped to the mouse genome
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with the preservation of canonical splice sites, compared to 87%
of introns in the pre-existing annotation, indicating that the
annotated introns show generally lower conservation. Secondly,
we examined whether there was a correlation between general
evolutionary conservation and the decision to annotate a
transcription event as coding. We found that 12.7% of the
additional exonic coverage in the annotation overlaps with
PhastCons elements,24 i.e. regions of the genome exhibiting
detectable sequence conservation, compared to 47% of pre-
existing exons. We next, randomly reassigned the sequences
across the genome sequence in order to obtain a background
estimate of conservation, ﬁnding that the resulting distribution is
centred around a 5% overlap following 1000 replicates (not
shown) and a one-sample t-test supports signiﬁcant enrichment in
the annotations with p < 2.2e−16. When considering only the 42 kb
of sequence annotated as coding, this proportion rises to 23%.
However, just 6% of all CDS exhibits the characteristic pattern of
protein sequence evolution, as judged by an examination of
overlap with regions of positive PhyloCSF score,25 compared to
91% of pre-existing coding exons. This may suggest that our
annotation has signiﬁcantly overestimated the proportion of the
transcribed sequence that is translated. Alternatively, it could be
that certain identiﬁed CDS regions have arisen in the primate
lineage following the divergence from the rodent clade.
In summary, while expression- and conservation-based
approaches do not provide vigorous support for the existence
of widespread functionality across the transcribed regions, they do
suggest that the reannotation of 191 genes has added a modest
subset of models with conserved biological roles.
Updated annotation identiﬁes putative clinically relevant variants
Given these considerations, we decided to investigate the clinical
impact of the annotations without initial regard to their expression
or conservation metrics. First, we compared the overlap of pre-
existing and updated annotation with the public variation dataset
in ClinVar <https://www.ncbi.nlm.nih.gov/clinvar/>. We note that
ClinVar is currently heavily biased towards ‘known’ gene
sequences in terms of content, i.e. disease-associated variants
are less likely to be found in regions that are less well studied (or
have been resequenced less often). Nonetheless, we found that 23
existing ClinVar variants could be made ‘exonic’ by our annota-
tions (Supplementary Data 1, sheet 1). This set does not include a
further 36 ClinVar variants that fall within 8 bp of an existing splice
site, due to the possibility that any pathogenicity associated with
these variants is due to the disruption of splicing and not directly
associated with the annotation (Supplementary Data 1, sheet 2).
Of immediate importance, within the 23 variants are
rs1555955290, rs1555955296 and rs1555955268, located within
close proximity in CDS added to CDKL5 (see Fig. 2). The ﬁrst variant
(rs1555955290) is a de novo variant recently identiﬁed in a child
with early onset seizures.26 This variant was recognised by the
authors as a 1-bp deletion in the CDS annotation based on RefSeq
coding model NM_001323289.1, which was created after the
annotation produced by our study was publicly released. Variant
rs1555955296 is also a de novo variant classed as pathogenic by
ClinVar, found in a patient classiﬁed as having early infantile
epileptic encephalopathy 2 by a clinical testing laboratory.
Interestingly, rs1555955268 is currently classiﬁed as ‘likely benign’
by ClinVar; this is a privately submitted germline variant from an
individual with an unspeciﬁed condition. Nonetheless, like
rs1555955296 which is 109 bp downstream, it is also a nonsense
variant. It would therefore be surprising if rs1555955268 does not
also turn out to have disease associations, although this remains
to be ascertained. Finally, we observe that a fourth ClinVar variant
(rs863225289) was initially ﬁltered out as it is found 3 bp
downstream of the pre-existing splice donor site. This variant
was also provided to ClinVar by a clinical testing laboratory, being
found in a patient with early infantile epileptic encephalopathy 2.
While the variant has been classed as pathogenic, it remains
unconﬁrmed whether the inferred causal effect is due to splicing
disruption or loss of function in the CDS.
Second, we focussed on a speciﬁc form of epilepsy linked to a
limited set of genes. DS is one of the best described and
genetically most homogeneous DEE syndromes.27 More than 80%
of DS cases are attributable to variants in SCN1A3 (OMIM ID:
607208) and about 700 pathogenic CDS variants have been
reported.28 Given the clear link between variants in SCN1A and DS,
any un-annotated exonic sequence is of potential clinical interest.
The updated SCN1A annotation identiﬁed nine exons, four shifted
splice junctions and a 3′ UTR (Fig. 3; Table 1), increasing the
genomic footprint of SCN1A transcription by ~3 kb (see Supple-
mentary Fig. 1 for an illustration of all splicing features in Table 1
for SCN1A).
At least two of these annotations have demonstrably added
biologically relevant sequences to the GENCODE catalogue. Firstly,
we found that one exon had in fact already been reported in the
human SCN1A literature, being described as alternatively spliced
with respect to canonical exon 5 in a mutually exclusive manner29
(feature 9; Table 1, Fig. 3). The inclusion of this alternative exon is
known to generate SCN1A isoforms that differ in their expression
pattern (with the exon preferentially expressed in neonatal brain,
as conﬁrmed by our analysis) and sensitivity to the antiepileptic
medications phenytoin and lamotrigine. Nonetheless, it appears
that this exon had not previously been included in any gene
annotation catalogues and we therefore presume it has also been
absent from SCN1A exome panels. Secondly, a poison exon
(feature 12) was also missing from GENCODE, despite the fact that
the orthologous exon in rat has been experimentally charac-
terised30 (feature 12; Table 1, Fig. 3). We report that this exon
incorporates ClinVar variant RCV000209951, an SCN1A de novo
variant found in a patient that was initially described as DS,31 but
after re-examination of the phenotype, appeared to have febrile
Fig. 1 Expression of transcripts. Cumulative distribution curves for the number of intron-supporting reads in pre-existing (GENCODE v20)
versus updated (GENCODE v28) annotation. Distribution curves for overall transcripts, CDS, 5′ and 3′ UTR are given. The x-axis is in log10 scale.
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seizures plus: he had his ﬁrst febrile seizure at the age of
23 months and later on developed afebrile tonic clonic seizures
and febrile status epilepticus. He had some mild speech delay, but
at the age of 11 years he had a normal development and was
seizure free for 2 years.32 The variant had been annotated as
intronic by ClinVar and thus of unknown signiﬁcance. Genome
alignments support the conservation of this exon across
vertebrate species. This variant has since been independently
characterised as a gain of function variant, promoting inclusion of
the poison exon and leading to reduction in the amount of SCN1A
protein.32
Two additional regions added to GENCODE, as part of this
study, exhibit strong markers for functionality at the transcript
level. The ﬁrst is an alternative ﬁrst exon consisting of 5′ UTR
sequence, found ~21 kb upstream of the previously recognised
5′ end of SCN1A (feature 1; Table 1, Fig. 3). This exon was
previously identiﬁed based on targeted sequencing of the
locus,33 although it was absent in annotation catalogues until
our work in this study. At the current time, there is limited
evidence for an association of this exon with disease,34 although
we suspect it remains largely unstudied in a clinical context.
Certainly, the biological validity of the exon is underpinned by
strong transcriptomics support in multiple data sources and also
the fact that it is conserved in mammalian and avian genomes,
with brain-speciﬁc transcriptomics support in mouse and
chicken (not shown). The second region also represents
additional 5′ UTR sequence, this time found as a cassette exon
in the ﬁrst intron following the ‘canonical’ SCN1A ﬁrst exon
(feature 2; Table 1, Fig. 3). Splice site conservation is observed
across to avian genomes (although with a 3-bp acceptor site
shift in certain lineages), with brain-speciﬁc RNA-Seq support in
chicken (not shown). Neither of these two novel regions
1
2
7 41219
ENST00000303395
SCN1A
Alt ﬁrst exon, 5’ UTR
Cassee exon, 5’ UTR
Poison exon Mutually exclusive exon Poison exon Poison exon
Fig. 3 The updated SCN1A annotation identiﬁed 10 exons and ﬁve shifted splice junctions, increasing the genomic footprint of SCN1A
transcription by ~3 kb. All features are described with respect to existing Ensembl model ENST00000303395 and numbered according to the
scheme used in Table 1. For clarity, the features are shown as truncated models containing only the exons of speciﬁc interest (and certain
features are present on multiple transcript models in the complete gene annotation). UTR sequences are shown in grey, coding or NMD
regions in black. Features [1] and [2] represent previously unreported 5′ UTR sequences that have conservation and equivalent expression in
mouse and chicken. Features [7] and [14] are cassette exons predicted to invoke NMD and contain the de novo variants identiﬁed in the study
within patients one and two respectively. Feature 9 is a cassette exon that is an ancient duplication of coding exon ﬁve, to which it is
transcribed in a mutually exclusive manner; the clinical signiﬁcance of this exon has been previously demonstrated by Tate et al. Feature 12 is
a cassette exon predicted to invoke NMD. Intron and exon sizes are to approximate scale. Additional transcript models have been omitted for
clarity.
ENST00000379996
CDKL5
ENST00000623535
170bp
1. rs863225289; C>T; Gln>Ter; pathogenic
2. rs1555955268; G>A; Trp>Ter; likely benign
3. rs1555955290; delGA; pathogenic
4. rs1555955296; C>T; Arg>Ter; pathogenic** **
1 2 3 4
3’ UTR
Fig. 2 Variants in coding sequence of CDKL5. ENST00000379996 had previously been annotated in GENCODE and represents a known
protein-coding transcript; coding exons 17–20 are shown (coding exons in black; UTR in grey). ENST00000623535 was annotated as part of
this study and the transcript contains an alternative CDS based on the usage of a different C-terminus, linked to a 3′ UTR sequence that
extends into an intron of ENST00000379996. This alternative 3′ UTR has strong support in polyAseq experiments and RNA-Seq assays across
multiple tissues (not shown). The 170 bp of CDS added to the intronic region contains 4 ClinVar variants, listed here by their dbSNP I.D.
alongside the consequences as presented by ClinVar. Bodian et al. recently reported rs1555955290 as a de novo frameshift variant in a child
with early onset seizures. Variants rs1555955296 and rs863225289 are de novo nonsense variants submitted to ClinVar by private testing
laboratories, both from people described as having early infantile epileptic encephalopathy 2. In contrast, nonsense variant rs1555955268 is
currently classiﬁed as ‘likely benign’ by ClinVar; this is a privately submitted germline variant from an individual with an unspeciﬁed condition.
Additional transcript models within the gene have been omitted for clarity.
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overlaps with any known disease-linked variants. However, as
noted, it should be considered that these regions have
apparently been hitherto unstudied in a clinical context.
To further investigate the value of our annotations in epilepsy
diagnostics, we screened a cohort of 122 people with DS or a
clinically similar phenotype for the added regions of SCN1A, plus
seven other genes with known associations to this disorder
(SCN2A, SCN1B, GABRA1, GABRG2, HCN1, CHD2 and PCDH19). Our
efforts in this study have increased the total transcript count of
these genes from 56 to 135. Cohort inclusion criteria were (1)
onset of seizures in the ﬁrst years of life, (2) presence of some
degree of developmental delay, (3) fever sensitivity and/or
prominent myoclonic seizures, leading to inclusion of people
with typical DS, but also clinically and genetically overlapping
syndromes such as myoclonic astatic epilepsy. All people had
previously undergone diagnostic genetic screening for variants in
epilepsy-associated genes including SCN1A, but no clear causal
variant had been identiﬁed. We identiﬁed two de novo variants in
SCN1A in two people (Fig. 4).
Patient one is a 15-year-old girl diagnosed with DS. Previous
screening efforts did not reveal a molecular diagnosis (including
SCN1A, STXBP1 and a gene panel35 consisting of known and
candidate genes for DS and Myoclonic Atonic Epilepsy). The de
novo variant identiﬁed here is found in an SCN1A poison exon
(feature 7 originally in intron 1; GRCh38 chr2: 166060831,
ENST00000636759.1:c.301 G > A; Table 1, Figs. 3 and 4). The
variant was validated with Sanger sequencing and maternity
and paternity was conﬁrmed using an in-house developed
multiplex PCR panel consisting of 16 STR-markers scattered over
the genome, including the X and Y chromosomes. She is the only
child of healthy non-consanguineous parents. The father had
photosensitive epilepsy as a child but is now seizure-free without
medication. A half-sister on the mother’s side has epilepsy but no
developmental delay. Due to the normal development of both the
father and the maternal half-sister and due to the lack of kinship
between father and half-sister, it is not expected that the family
members share the same genetic variant as the proband to
explain their epilepsy. However, it cannot be excluded that the
father has a low-grade mosaicism for the SCN1A variant that was
not detected through Sanger sequencing. The proband ﬁrst
presented with febrile seizures when she was 8 months old. She
had focal impaired awareness seizures and later also developed
afebrile tonic-clonic seizures starting at 18 months old that
occurred very frequently until the age of 5 years. She also had
absences and myoclonic seizures. Electroencephalograms (EEG)
showed background slowing and paroxysmal slow spike and spike
waves. Development was normal prior to seizure onset, but
slowed soon after, resulting in moderate intellectual disability.
Brain MRI imaging showed no abnormalities and normal spectro-
scopic sequences. She is currently being treated with a combina-
tion of levetiracetam, topiramate, clobazam and stiripentol, but
still has frequent tonic-clonic seizures.
Patient two is a 14-year-old girl diagnosed with DS. Previous
screening of SCN1A, PCDH19 and HCN1 did not result in the
identiﬁcation of a pathogenic variant. Our study identiﬁed a de
novo variant in a different poison exon of SCN1A (feature 14
originally in intron 22; GRCh38 chr2: 165999107,
ENST00000635893.1:c.79 G > A; Table 1, Figs. 3 and 4). The variant
was validated with Sanger sequencing and maternity and
paternity conﬁrmed using the same in-house developed multiplex
PCR panel. She is born from healthy non-consanguineous parents.
There is no familial history of epilepsy. The proband had her ﬁrst
febrile seizure evolving to status epilepticus when she was
6 months old. She further had, on average, six or seven episodes
of generalised tonic-clonic status epilepticus per year, mostly with
fever. After seizure onset her development slowed, resulting in
moderate intellectual disability. Other comorbidities include
ataxia, orofacial dyspraxia, difﬁculties with ﬁne motor skills,
Table 1. List of all features identiﬁed within SCN1A.
Feature Feature type Feature length Chr position (GRCh38) Feature
position
Transcript
biotype
Transcript region Feature
conservation
1 Exon 168 nt chr2:166,149,047–166,149,214 Terminal Coding 5′ UTR Yes
2 Exon 87 nt chr2:166,126,924–166,127,010 Internal Coding 5′ UTR Partial - splice
donor conserved
3 Exon 73 nt chr2:166,126,982–166,127,055 Terminal Coding 5′ UTR No
4 Exon 111 nt chr2:166,126,924–166,127,034 Terminal Retained intron 5′ UTR Yes
5 Splice acceptor 46 nt extension chr2:166,077,802–166,077,848 Internal Coding 5′ UTR No
6 Exon 264 nt chr2:166,071,623–166,071,886 Internal Processed
transcript
n/a No
7 Exon 228 nt chr2:166,060,640–166,060,867 Internal NMD CDS No
8 Splice acceptor 4 nt extension chr2:166,056,501–166,056,504 Internal NMD CDS Yes
9 Exon 92 nt chr2:166,053,039–166,053,130 Internal Coding CDS Partial - splice
acceptor
conserved
10 Splice acceptor 3 nt truncation chr2:166,045,325–166,045,327 Internal Coding CDS Yes
11 Splice donor 16 nt extension chr2:166,041,215–166,041,230 Internal NMD CDS Yes
12 Exon 64 nt chr2:166,007,230–166,007,293 Internal NMD CDS Yes
13 Intron Skips 282 nt exon chr2:166,002,471–166,002,752 Internal Coding CDS Yes
14 Exon 66 nt chr2:165,999,051–165,999,116 Internal NMD CDS No
15 Intron retention Retains ﬁnal intron
of 1723 nt
chr2:165,992,413–165,994,147 Terminal Coding CDS Yes
A single Ensembl transcript model is listed for all features; certain features are also present in other models. ‘Biotype’ details the functional effect of the feature
as inferred by manual annotation. The alternative ﬁnal exon within model ENST00000642141 was annotated as ‘non-coding’ due to the absence of
polyadenylation data as per GENCODE guidelines; the functional status of this model is in reality unknown. Feature conservation describes the annotation and
structurally identical feature in the mouse ortholog Scn1a
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hyperkinesia and sleep disturbances. EEG at the age of 5 years
showed bifrontal slow waves and rare temporal spikes. MRI was
normal apart from an asymptomatic pituitary cyst. She is currently
being treated with a combination of valproate, clobazam and
topiramate, which has reduced seizure frequency.
To quantify the signiﬁcance of de novo variant enrichment in
the 450 bp of CDS sequences (sum of features 7, 9, 12 and 14 from
Table 1) and to estimate the probability of identifying two or more
de novo variants in a cohort of 122 sequenced probands, we
performed a de novo variant enrichment statistical test using the
ﬁtDNM package.36 This package returns the Poisson unweighted
P-value based on expected mutability rate and shows that it is
improbable to observe two de novo variants among 122
individuals along this stretch of 450 bp of CDS (unadjusted p=
9.5 × 10−7). Even after conservative exome-wide multiple testing
correction for 18,000 possible protein-coding genes, this remains
signiﬁcant (p= 0.017), conﬁrming a signiﬁcant enrichment of de
novo variants in the SCN1A sequences.
Neither poison exon is well conserved (PhastCons scores 0.102
and 0.000 for the two variants respectively). Both variants were
predicted to alter binding sites for hnRNP A1, which is a splice
‘silencer’ that promotes exon skipping.37,38 We, therefore,
postulate that the alterations of these respective motifs could
lead to increased inclusion of the poison exons and therefore a
reduction in the production of SCN1A protein due to NMD. Further
functional work will be needed, however, to validate this
hypothesis.
DISCUSSION
We have used human brain-transcriptomic data to rigorously
interrogate the human reference transcriptome for missing
transcriptional features, focusing on 191 genes associated with
DEE. We investigated a cohort of people with DS, which has a
robust phenotype/genotype correlation with SCN1A, with the
presumption being that any such exon features that capture a
variant in SCN1A could support a diagnosis. On investigation, we
ENST00000635893.1
patient 2
c.79 G>A
ENST00000636759.1
patient 1
c.301 G>A
Family 1
G G A G T G C A G/A T G G C G C G A
G G A G T G C A G T G G C G C G A G G A G T G C A G TG G C G C G A
Family 2
C T C T T T C A G/AG C T C C A A G
C T C T T T C A G G C T C C A A G C T C T T T C A G G C T C C A A G
a)
b)
hnRNP A1 consensus (SELEX) T A G G G A  100
hnRNP A1 consensus (Beusch et al.)  T C A G T  T (N) T T A G G T C
WT NMD transcript 1 C G A G T  G - - C A G T  G G  66,67
var NMD transcript 1 C G A G T  G -
WT NMD transcript 2 C C A G A A ATCCTCTT  T C A G G C T   73,81
var NMD transcript 2 C C A G A A ATCCTCTT  T C A A G C T   <65,48 (site broken)
Motif value (HSF)
c)
- C A A T  G G  <65,48 (site broken)
SCN1A transcript
Alternative 
transcripts
Fig. 4 Variants in coding regions are associated with DS. a Pedigrees and Sanger sequencing traces of the two families with a de novo SCN1A
variant in the identiﬁed poison exons. b The two transcripts containing the variants, relative to the full-length transcript. Red exons are coding,
white exons are non-coding. c Variants are predicted to disrupt a hnRNP A1 recognition site.
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identiﬁed three de novo variants within three distinct poison
exons of the SCN1A gene that are associated with DS, each of
which is absent from current diagnostic tests. Many studies have
underlined the important contribution of de novo variants in the
aetiology of DEE,2 making such variants of particular interest to
the clinician. Variants in poison exons have been previously
described to cause Mendelian disorders, via mechanisms pro-
posed to affect the level of protein expression.39,40 Haploinsufﬁ-
ciency of SCN1A is a cause of DS and it therefore seems reasonable
to speculate that a higher inclusion of any of these poison exons
could lead to a net reduction of functional protein and thus the
disease phenotype; this has in fact now been established for
ClinVar variant RCV000209951 in the poison exon described by
Carvill et al.32 For the two de novo variants ﬁrst reported here, we
recognise that similar efforts to ascribe true pathogenicity will
now be required, which is complicated by the neuron-speciﬁc
expression pattern of SCN1A. However, given the strong and
clearly established genotype–phenotype correlation between DS
and SCN1A, it is appropriate to consider these two de novo
variants as strong candidates for driving pathogenicity at the
current time, not least because making this genetic diagnosis can
underpin potentially life-saving changes to medication, as well as
informing prognosis and stopping further unnecessary investiga-
tions. We emphasise that these are de novo variants and their
absence in ~15,500 genomes in gnomAD36 is consistent with
negative selection in human populations. Also, the observation of
multiple disease-linked variants within the total 450-bp space of
predicted coding or NMD-triggering sequence is highly improb-
able among just 122 probands - considering also that the average
human is expected to have around 70 single nucleotide de novo
variants in total41- which suggests they have been identiﬁed due
to the ascertainment for a cohort of molecularly undiagnosed DS
probands.
Nonetheless, it is striking that only the poison exon overlapping
ClinVar variant RCV000209951 exhibits notable evolutionary
conservation. This point is of immediate practical importance
because the de novo variants reported here are at risk of being
ﬁltered out by prioritisation algorithms that utilise conservation
metrics. These ﬁndings may also be surprising from a biological
point of view, i.e. considering potential mechanisms of patho-
genicity, given the traditional weight placed on the maxim that
‘conservation= function’. However, while gene-level conservation
is typically studied in the context of protein-coding sequences, far
less is known about the evolutionary dynamics of gene regulatory
programmes linked to alternative splicing. These concepts may be
especially relevant to the brain, which is known to be particularly
rich in alternative splicing compared to other organs and tissues.42
Indeed, given that the human brain has evolved and enlarged
considerably with respect to apes over the past 2.5 million years,43
we can speculate that functionality is generally linked to newly
evolved sequences.44 Nonetheless, we also observed that the
transcriptional support for both poison exons is not strong. These
observations would be reconciled with our inferences into
pathogenicity if the de novo variants do indeed turn out to lead
to increased inclusion of the poison exons. It would therefore be
informative to know whether these exons have higher levels of
inclusion in the two DS people.
Extrapolating from this discussion, we consider that all of the 3550
transcripts annotated here within an exemplar set of 191 genes
associated with epilepsy are of potential clinical interest. However,
we recognise that detailed work will be required to establish which
of these de novo variants have a true clinical association with
epilepsy, as well as the biological mechanisms by which they drive
disease. A logical next step would be to resequence these regions in
people with epilepsy that lack a molecular diagnosis. In the
meantime, it may be of interest to note that we also added two
poison exons to SCN8A and ﬁve to SCN2A, which are recognised as
brain-expressed sodium channel genes. These exons are apparently
absent from other annotation catalogues or exome panels and we
observe that four are conserved, at least across the mammalian
order (GRCh38 chr12:51768113-51768172; chr12:51780202-
51780271; chr2:165328404-165328538; chr2:165357774-
165357857 (this feature will appear for the ﬁrst time in
GENCODEv33)).
We recognise that the value of adding large numbers of
additional transcribed regions to disease-linked genes could be
questioned, while it remains unclear exactly which transcript
models have biological relevance. Broadly speaking, diagnostics
based on expanded gene annotation has the potential to reduce
false negative variant interpretations (i.e. to incorporate important
‘missed’ variants) at the expense of an increase in false positives.
As discussed, our SCN1A variant interpretations beneﬁt from the
high concordance between perturbations to this gene and DS, as
well as the fact that these are de novo variants. It is less certain
how expanded annotation would perform in clinical scenarios
where this is not the case. For example, hundreds of genes have
now been linked to autism spectrum disorder with varying
degrees of conﬁdence and this disorder has a far more
heterogeneous causation than DS.42 In our view, identiﬁed
sequences with strong markers for functionality – especially those
that can be established as coding sequences based on
evolutionary conservation and/or proteomics data – should be
considered those most likely to have functionality and therefore
those with the most potential value in the search for undiscovered
disease-linked variants. Nonetheless, our work here illustrates that
a consideration of the full transcriptional proﬁle of a gene can also
be fruitful, i.e. including transcripts with poor conservation and
weak transcription and those that do not appear to encode
proteins. As discussed, we believe this point is particularly
apposite when considering that pathogenicity can also arise from
gain of function modes.
Finally, establishing a genetic cause for epilepsy in an individual
is a key step in clinical management. It provides an explanation,
terminates the diagnostic odyssey and may inform treatment
options and prognostication. Furthermore, it helps with determin-
ing other management issues (e.g. known associated comorbid-
ities like gait disorders, involvement of other organs, dysphagia),
genetic counselling and overall care, where having a name for a
condition typically facilitates access to services. Importantly, it also
provides a label and typically relieves parental guilt. Last, but not
least, identifying the genetic cause of a severe disease can have
direct therapeutic implications, like avoiding the use of sodium
channel blockers, or using stiripentol as add-on therapy,45 in DS
caused by SCN1A variants. Current methods of establishing a
genetic diagnosis in clinical settings consist of candidate gene
analysis, gene panel or WES and array comparative genomic
hybridisation to identify copy number variants (CNVs). If these
methods are undertaken and no variant is found, such cases
usually go into research projects, which generally take longer and
are more uncertain. If the original tests to establish a diagnosis are
missing annotation, this all leads to costly and unnecessary delays,
both for patients, their family and for the healthcare system. This
study further raises the question whether it would be more
desirable to use WGS for diagnostic purposes, as data can be
iteratively re-annotated when updated annotation information
becomes available. Similarly, this approach has already been
proven successful as iteratively re-analysing patient genomes
when new causative genes are discovered increases diagnostic
yield.7,46
In summary, our ﬁndings suggest that there are potentially
additional causative genetic variants to be identiﬁed in and
around epilepsy-related genes such as SCN1A, including in
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predicted poison exons. We anticipate that the inclusion of the
transcripts identiﬁed here will further increase the number of
variants found in SCN1A in people with DS. Furthermore, if the
same approach we have taken to SCN1A and DS is applied to other
focussed cohorts for the other 190 genes in our study, we would
expect to ﬁnd resolvable cases in the gene that was originally
suspected by the clinician.
METHODS
Selection of genes
191 genes associated with deleterious variants implicated in epilepsy in
general and DEE in particular were included in this study. These included
66 genes from the Great Ormond Street Hospital (GOSH) for Children,
London, UK, Early Infantile Epileptic Encephalopathy (EIEE) gene-panel
(http://www.labs.gosh.nhs.uk/media/759010/eiee_v7.pdf), selected as
established causes of early-onset seizures and/or severe developmental
delay in patients without frequent major structural brain anomalies. Genes
leading to neurometabolic disorders with readily identiﬁable blood/urine/
cerebrospinal ﬂuid (CSF) biomarkers were not included. An additional 58
genes were included from the Addenbrooke’s Hospital, Cambridge, UK,
EIEE gene panel, as well as 14 genes from the DDD study47 and 53 genes
from literature searching. The full list can be found in Supplementary
Data 2.
Gene annotation
Manual re-annotation of the 191 genes was performed on GRCh38 (https://
www.ncbi.nlm.nih.gov/grc/human) according to the guidelines of the
HAVANA (Human And Vertebrate Analysis and Annotation) group48 (and
ftp://ftp.sanger.ac.uk/pub/project/havana/Guidelines/Guidelines_-
March_2016.pdf). In summary, the HAVANA group produces annotation,
largely based on the alignment of transcriptomic (ESTs and mRNAs) and
protein sequence data from GenBank49 and Uniprot.50 These data were
aligned to the individual bacterial artiﬁcial chromosome clones that make
up the reference genome sequence using BLAST51 with a subsequent
realignment of transcript data by Est2Genome.52 In addition, SLR-RNA-Seq
data53 mapped using Gmap,54 PACBIO55 reads mapped using STAR56 and
foetal and infant RNA-Seq data19 mapped using cufﬂinks,57 were also used
to identify transcripts and splice junctions. Data are available at www.
gencodegenes.org/releases/. Updated annotation of the 191 genes
described in this study on GRCh38 is represented in GENCODE releases
from v27 (August 2017) onwards. In addition, the updated annotation is
available remapped to GRCh37 [https://github.com/diekhans/gencode-
backmap] here: http://www.gencodegenes.org/releases/grch37_mapped_
releases.html.
Identiﬁcation of splicing events
Transcript structures in public releases of GENCODE before (GENCODE v20)
and after (GENCODE v28) the manually updated annotations were
compared to ﬁnd exons, introns and shifted splice junctions. The number
of genomic bases covered by the extended gene annotation and coding
sequence was calculated using a custom Perl script. Exons are deﬁned as
those in the updated annotation that shared no sequence with any exon in
the previous annotation. Introns were those introns in the updated
annotation that did not match exactly an intron in the old annotation.
Shifted splice junctions occurred when an exon in the updated annotation
shares an overlap with an exon in the old annotation but at least one of
the splice sites was not in the same location. Retained intron transcripts
were excluded from this analysis. RefSeq annotation for transcript counting
was extracted from the Ensembl release 84 (March 2016) “RefSeq GFF3
annotation import”.
Identiﬁcation of transcriptional features on GRCh38 using foetal
and infant RNA-Seq data
Illumina data from Jaffe et al.19 was re-mapped for foetal and infant
transcriptome to GRCh38 to identify transcriptional features. FASTQ ﬁles
from the following datasets were downloaded from ENA: SRR1554537,
SRR1554538, SRR1554541, SRR1554544, SRR1554546, SRR1554549,
SRR1554551, SRR1554553, SRR1554554, SRR1554566, SRR1554567 and
SRR1554568. Data were mapped to GRCh38 with TopHat (tophat-2.0.13).58
Reads mapping to the gene regions that were studied, were merged into
two ﬁles containing foetal and infant alignments using SAMtools.59
Transcript models were generated from the foetal and infant BAM ﬁles
using Cufﬂinks (cufﬂinks-2.2.1).58 Introns and splice sites were identiﬁed, a
BED ﬁle generated and passed to manual annotators for checking.
Quantiﬁcation of gene expression at exon level
Raw reads from Jaffe et al.,19 were available via study accession SRP045638.
The 36 paired-end libraries were analysed using the iRAP pipeline (https://
github.com/nunofonseca/irap). First, raw reads in the original FASTQ ﬁles
underwent quality assessment and ﬁltering.60 They were then aligned
against the GRCh38 genome reference using Tophat2,61 with the option:
‘–min-intron-length 6’.
Analysis of expression of splice features
Integrative Pipeline for Splicing Analyses (IPSA)62 was employed to
produce splice junctions and their read counts from Tophat2 alignments
of Jaffe et al.19 on GRCh38 human genome. This analysis included 36
human brain pre-frontal cortex samples, corresponding to six different
developmental stages (Foetal, Infant, Child, Teen, Adult and Old).19 IPSA
was run with the default parameters and the pre-annotation update
release GENCODE v20 as a reference. Transcript expression levels around
introns were estimated from the number of reads supporting the
respective splice junction. Expression of splice junctions was normalised
by the total number of reads in each sample.
Mapping annotation from reference human genome to mouse
genome
The TransMap cross-species alignment algorithm was used to map all
annotated transcripts from the reference human genome (GRCh38) to the
reference mouse genome (GRCm38). The alignments are created using
synteny-ﬁltered pairwise genome alignments (chains and nets) produced
using BLASTZ.23,63,64 All transcript models mapped to mouse were
manually-assessed to identify failures to align correctly at the base, exon
and intron level.
Identiﬁcation of conservation of coding sequence
The DEE gene annotation was obtained by subtracting the GENCODE v20
gene annotation from the current one (equivalent to GENCODE v28) using
“bedtools subtract” separately for exon and CDS regions. The RepeatMas-
ker repeat features (except low complexity elements) extracted from
Ensembl were subsequently subtracted from this annotation. The ﬁltered
annotation was then intersected with:
(a) phastConsElements100way.bed obtained from the UCSC Table
Browser (https://genome.ucsc.edu/cgi-bin/hgTables);
(b) 27 amniota vertebrates GERP constrained elements from Ensembl
(ftp://ftp.ensembl.org/pub/release-90/bed/ensembl-compara/
27_amniota_vertebrates_gerp_constrained_elements/
gerp_constrained_elements.homo_sapiens.bed.gz);
(c) PhyloCSF (58 mammals) approximate coding regions from the
PhyloCSF track hub (https://data.broadinstitute.org/compbio1/
PhyloCSFtracks/trackHub/hg38/trackDb.txt).
In all cases, the overlap with the DEE gene annotation was carried out
using “bedtools intersect”.
Identiﬁcation of variants in updated annotation
The collection of variants available under “All phenotype-associated - short
variants (SNPs and indels)” in Ensembl release 90 (August 2017) was
intersected separately with the exons in GENCODE 20 and in the current
annotation, using a custom Perl script and the Ensembl API. The variants
overlapping the current annotation, but not GENCODE 20, were reported.
A second round was carried out, considering only the 8-nt exon ﬂanking
sequences in both annotation sets.
As a proof-of-concept, we screened a cohort of 122 people with DS or a
clinically similar severe myoclonic epilepsy phenotype for the 125 regions
identiﬁed from this study of all genes that have previously been associated
with DS (SCN1A, SCN2A, SCN1B, GABRA1, GABRG2, HCN1, CHD2 and
PCDH19), using an amplicon targeted ampliﬁcation assay (Agilent, https://
www.agilent.com). All samples underwent diagnostic screening for SCN1A
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(including both sequencing and CNV analysis), but no pathogenic variants
had been identiﬁed, after which they were included in research.
Additionally, several patients were screened for genetic variants in
epilepsy-associated genes using Sanger sequencing, gene panels or WES.
Primers for the multi-amplicon target panel were designed using the
mPCR software (Agilent).65 Speciﬁc target regions were ampliﬁed using
multiplex PCR, followed by puriﬁcation of the equimolar pooled amplicons
using Agencourt AMPureXP beads (Beckman Coulter, CA, USA). Individual
barcodes (Illumina Nextera XT) were incorporated in a universal PCR step
prior to sample pooling. Libraries were sequenced on a MiSeq platform
using v3 reagent kit with a paired-end read length of 300 bp
(Illumina, USA).
Analysis was performed in-house with a standardised pipeline
integrated in genomecomb.66 The pipeline used fastq-mcf (https://
expressionanalysis.github.io/ea-utils/) for adapter clipping. Reads were
then aligned using BWA-MEM67 and the resulting SAM ﬁle converted to
BAM using Samtools.59 BAM ﬁles were sorted using biobambam.68
Realignment in the neighbourhood of indels was performed with GATK.69
Amplicon primers were clipped using genomecomb.66 Variants were called
at all positions with a total coverage ≥5 using both GATK69 and Samtools.59
At this initial stage, positions with a coverage <5 or a score <30 were
considered unsequenced. The resulting variant sets of different individuals
were combined and annotated and ﬁltered using genomecomb.66
Variants with a coverage above seven and a GATK quality score above
50 that were identiﬁed by both variant callers (GATK and Samtools) and
were absent in publicly available databases (gnomAD,70 1000 Genomes,71
Exome Variant Server (http://evs.gs.washington.edu/EVS/)) and our in
house database, were extracted. Furthermore, variants present in
homopolymer regions (>8 homopolymers) or simple repeat regions were
excluded. The effect of the variant was predicted with the Ensembl Variant
Effect Predictor (VEP),72 using the manually annotated GENCODE dataset
as custom gene annotation. Variants were validated and the segregation
was checked using bi-directional Sanger sequencing. For de novo variants,
maternity and paternity was conﬁrmed using an in-house developed
multiplex PCR panel consisting of 16 STR-markers scattered over the
genome, including the X and Y chromosome.
To predict the effect of the de novo variants on splicing efﬁciency, we
used the ‘quick mutant’ analysis from Human Splicing Finder,73 using the
CDS from the NMD transcripts as custom sequence input.
Testing for signiﬁcant excess of de novo variation among SCN1A
CDS protein-coding sequence
The genomic sequences corresponding to protein-coding features of
SCN1A (Features 7, 9, 12 and 14; Table 1) were concatenated to reﬂect a
consecutive test sequence of length 450 bp on GRCh38. To test whether
the observed number of two de novo variants among this stretch of
450 bp was signiﬁcant, based on a sampled cohort of 122 individuals, we
adopted a modiﬁed version of R package ﬁtDNM.36 The published ﬁtDNM
provides both a PolyPhen-2 weighted and Poisson unweighted p-value.
Here, since PolyPhen-2 scores do not exist for the entirety of the CDS
sequence we focus on the Poisson unweighted P-value. The modiﬁcation
to the original ﬁtDNM package was to correct a type conversion error,
which possibly occurred due to different versions of R used for our analysis
(v3.5.0) compared to the original package version. Speciﬁcally, we ﬁxed a
clash where a ‘T’-valued variable (intended for Thymine) was handled as
“TRUE”. The adapted ﬁtDNM package accompanied by input and output
ﬁles from this analysis are available upon request. This R package then
takes as input the underlying mutability of the 450 bp (Supplementary
Data 3), the total number of observed de novo variants among that 450
bases of sequence and the total number of probands tested for a de novo
variant in that 450 bases of sequence. Subsequently, we conservatively
corrected the resulting Poisson unweighted P-value by 18,000 to reﬂect
approximately the total number of WES studied protein-coding genes in
the human exome.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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